At Isomorphic Labs, we collaborate with various companies to generate proprietary data, which has proven to be impactful in drug development.

The ambition at Isomorphic Labs is to develop a drug design engine that can continuously adapt and apply to new challenges across different diseases, fundamentally changing drug discovery.

AlphaFold 3 enables drug designers to model not just protein structures but also how these proteins interact with small molecules, enhancing our ability to design effective drugs.

AlphaFold 3 allows our drug designers to see how their molecule designs interact with protein targets instantly, which is a game changer in drug design.

Before AlphaFold 3, drug designers had to rely on intuition and lengthy lab processes to understand molecular interactions, which is no longer the case.

The first generation of AI applications in drug design often focused on local models, but our approach is to build a more comprehensive system that can generalize across various tasks, as demonstrated by AlphaFold 3, which allows us to create models that generalize across chemistry and target space, enabling application to any protein or small molecule without needing fine-tuning.

To achieve transformative drug design, we need several more breakthroughs similar to AlphaFold, focusing on different core concepts of biology and chemistry.

AlphaFold 3 represents a significant breakthrough in understanding biomolecular structure, allowing for experimental-level accuracy in predicting protein structures and their interactions with small molecules, DNA, and RNA.

AlphaFold has become a standard tool for biology and medical research, with over 2.5 million researchers worldwide using it in their critical work, significantly impacting the scientific community.